Amylyx Pharmaceuticals Inc (NASDAQ: AMLX) closed the day trading at $3.36 down -82.29% from the previous closing price of $18.97. In other words, the price has decreased by -$15.6100 from its previous closing price. On the day, 61177212 shares were traded.
Ratios:
For a better understanding of AMLX, let’s look at its different ratios. It provided that stocks Price–to–Cash (P/C) ratio for the trailing twelve months (TTM) is standing at 0.61 whereas its Price-to-Free Cash Flow (P/FCF) for the term is 21.30. For the most recent quarter (mrq), Quick Ratio is recorded 5.20 and its Current Ratio is at 5.66. In the meantime, Its Debt-to-Equity ratio is 0.01 whereas as Long-Term Debt/Eq ratio is at 0.00.
On January 03, 2024, Robert W. Baird started tracking the stock assigning a Outperform rating and target price of $37.Robert W. Baird initiated its Outperform rating on January 03, 2024, with a $37 target price.
Insider Transactions:
The insider trade also gives investors a glimpse into the future direction of stock prices, which can be beneficial to investors. A recent insider transaction in this stock occurred on Mar 05 ’24 when Klee Justin B. sold 4,135 shares for $18.73 per share. The transaction valued at 77,440 led to the insider holds 2,959,308 shares of the business.
Cohen Joshua B sold 4,135 shares of AMLX for $77,440 on Mar 05 ’24. The Co-Chief Executive Officer now owns 3,023,002 shares after completing the transaction at $18.73 per share. On Mar 05 ’24, another insider, FRATES JAMES M, who serves as the Chief Financial Officer of the company, sold 1,792 shares for $18.73 each. As a result, the insider received 33,560 and left with 134,784 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, AMLX now has a Market Capitalization of 227.75M and an Enterprise Value of -139.38M. As of this moment, Amylyx’s Price-to-Earnings (P/E) ratio for their current fiscal year is 4.77, and their Forward P/E ratio for the next fiscal year is 2.23. For the stock, the TTM Price-to-Sale (P/S) ratio is 0.60 while its Price-to-Book (P/B) ratio in mrq is 0.52. Its current Enterprise Value per Revenue stands at -0.37 whereas that against EBITDA is -3.49.
Stock Price History:
Over the past 52 weeks, AMLX has reached a high of $38.32, while it has fallen to a 52-week low of $11.82. The 50-Day Moving Average of the stock is 15.9835, while the 200-Day Moving Average is calculated to be 18.5744.
Shares Statistics:
Over the past 3-months, AMLX traded about 1.24M shares per day on average, while over the past 10 days, AMLX traded about 7.53M shares per day. A total of 67.71M shares are outstanding, with a floating share count of 51.63M. Insiders hold about 23.74% of the company’s shares, while institutions hold 89.52% stake in the company. Shares short for AMLX as of Feb 15, 2024 were 4.98M with a Short Ratio of 4.02, compared to 5.73M on Jan 12, 2024. Therefore, it implies a Short% of Shares Outstanding of 7.35% and a Short% of Float of 9.78%.
Earnings Estimates
Current recommendations for the stock of the company come from 5 analysts. On average, analysts expect EPS of $0.15 for the current quarter, with a high estimate of $0.3 and a low estimate of $0.06, while EPS last year was $0.02. The consensus estimate for the next quarter is $0.22, with high estimates of $0.4 and low estimates of $0.08.
Analysts are recommending an EPS of between $2.13 and $0.36 for the fiscal current year, implying an average EPS of $1. EPS for the following year is $1.55, with 7 analysts recommending between $3.32 and $0.63.
Revenue Estimates
5 analysts predict $112.57M in revenue for the current quarter. It ranges from a high estimate of $114.86M to a low estimate of $109.2M. As of the current estimate, Amylyx Pharmaceuticals Inc’s year-ago sales were $71.43M, an estimated increase of 57.60% from the year-ago figure. For the next quarter, 5 analysts are estimating revenue of $119.99M, an increase of 22.20% less than the figure of $57.60% in the same quarter last year. There is a high estimate of $122.69M for the next quarter, whereas the lowest estimate is $114.4M.
A total of 7 analysts have provided revenue estimates for AMLX’s current fiscal year. The highest revenue estimate was $499.7M, while the lowest revenue estimate was $448.4M, resulting in an average revenue estimate of $483.1M. In the same quarter a year ago, actual revenue was $380.79M, up 26.90% from the average estimate. Based on 7 analysts’ estimates, the company’s revenue will be $579.29M in the next fiscal year. The high estimate is $713.33M and the low estimate is $520.26M. The average revenue growth estimate for next year is up 19.90% from the average revenue estimate for this year.
